间变性淋巴瘤激酶阳性非小细胞肺癌脑转移靶向治疗及联合放疗的治疗进展

Advances on Targeted Therapy Combined with Radiotherapy for Brain Metastasis in Patients with Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer

非小细胞肺癌(non-small cell lung cancer,NSCLC)患者基因突变发生率较高,间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)阳性是NSCLC中常见的基因突变类型之一。酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗过程中,脑转移通常是疾病进展的首要原因。因此,ALK阳性NSCLC患者的脑转移治疗显得极为重要。ALK-TKI与放疗联用可能对脑转移的治疗产生协同效应,不过也增加了神经损伤和认知功能下降的风险。关于ALK阳性NSCLC脑转移的治疗相关研究较少,ALK-TKI的作用机制以及放疗如何与ALK-TKI联用形成最佳治疗方案仍值得进一步探讨。全文就ALK阳性NSCLC脑转移的ALK-TKI治疗及联合放疗的进展简要综述。

The incidence of gene mutation in non-small cell lung cancer(NSCLC)is high,anaplastic lymphoma kinase(ALK)positive is one of the common types of gene mutation in NSCLC.Brain metastasis is usually a primary cause of disease progression during the treatment with ALK tyrosine kinase inhibitor(ALK-TKI).ALK-TKI combined with radiotherapy may have a synergistic effect on the treatment of brain metastasis,but it also increases the risk of neurological damage and cognitive decline.There are few studies on the treatment of brain metastasis of ALK positive NSCLC.The mechanism of ALK-TKI and radiotherapy combined with ALK-TKI to form a optimal treatment plan are still worthy of further discussion.This article reviews the progress of ALK TKI therapy combined with radiotherapy for brain metastasis in patients with ALK positive NSCLC.